

#3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: HSHAO et al.
Application No: Initial Filing
International Filing Date: 27 June 2003
Priority Date: 27 June 2002
International Appl. No.: PCT/US2003/020587
Attorney Docket Number: 32144183.4
For: PLASMA OR SERUM MARKER AND PROCESS FOR
DETECTION OF CANCER

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Commissioner:

INFORMATION DISCLOSURE STATEMENT

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant(s) hereby notify the U.S. Patent and Trademark Office of the document(s) which is/are listed on the attached Form PTO-SB/08A. Copies of references are enclosed.

 X (1) This IDS does NOT require a fee or 37 C.F.R. § 1.97(e) statement because it is being filed (check all that apply):

 X (a) Within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); **OR**

 (b) Within three months of the date of entry of the national stage as set forth in § 1.491 in an international application; **OR**

 (c) Before the mailing of a first Office action on the merits; **OR**

☐ (d) Before the mailing of a first Office action after the filing of a request for continued examination under § 1.114.

☐ (2) This information disclosure statement is filed before the mailing date of a final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application, and (check only one):

☐ (a) Is accompanied by the fee set forth in § 1.17(p); **OR**

☐ (b) Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; **OR**

☐ (c) No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.

☐ (3) This Information disclosure statement is filed on or before payment of the issue fee and is accompanied by the fee set forth in § 1.17(p); **AND** (check only one):

☐ (a) Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; **OR**

☐ (b) No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the person signing the certification after making reasonable inquiry, no item of


information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant(s) does/do not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

Please charge any necessary fee or credit any overpayment in connection with this Information

Disclosure Statement to Deposit Account No. 13-0480 (please reference 32144183.4).

Respectfully submitted,



Pamela J. Wong
Attorney for Applicant
Reg. No. 54,765

12/3/2004

BAKER & MCKENZIE
2300 Trammell Crow Center
2001 Ross Avenue
Dallas, Texas 75201-2916
Main: (214) 978-3000
Direct: (619) 235-7792
Fax: (214) 978-3099

10/516864

DT05 Rec'd PCT/PTO 03 DEC 2004

PTO/SB/08B (02-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	Initial Filing
		Filing Date	
		First Named Inventor	HSIAO et a.
		Art Unit	Not yet assigned
		Examiner Name	Not yet assigned
Sheet 2	of 2	Attorney Docket Number	32144183.4

OTHER PRIOR ART–NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		MULCAHY et al. Cancer and mutant DNA in blood plasma. The Lancet. 07 September 1996, Vol. 348, pp. 28.	
		ANKER et al. Detection of circulating tumour DNA in the blood(plasma/serum) of cancer patients. Cancer and Metastasis Reviews. 1999, Vol. 18, pps. 65-73.	
		VALIZADEH et al. Expression of E-cadherin-associate molecules (alpha, beta and gamma-catenins a p 120) in colorectal polyps. Am. J. Pathology. June 1997, Vol. 150, No. 6 pps. 1977-1984	
		QIN et al. The prognostic molecular markers in hepatocellular carcinoma. World AJ. Gastroenterol. 2002, Vol. 8, No. 3, pps. 385-392.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, Washington, DC 20231.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.